Participants
ONCOLOGY, DISEASE
Eligible patients were ≥18 years of age, had a known diagnosis of MM with evidence of measurable disease, had received prior treatment with an IMiD and a PI, and had received ≥3 prior lines of therapy. Patients who previously received other anti‐CD38 mAbs were allowed if treatment was beyond 90 days from study entry, and if refractory, the last exposition was beyond 6 months. Exclusion criteria included prior exposure to isatuximab or any agent that blocks the PD‐1/PD‐L1 pathway; Eastern Cooperative Oncology Group performance status (ECOG PS) >2; and inadequate hematological, liver, or renal function.